The Opportunity

The Ophthalmic drug industry grosses over $1.8 billion Canadian annually and is the fastest growing segment of the Canadian pharmaceutical industry. Genix’s plan in the future is to research ocular herbal products and acquire an additional 70-100 ophthalmic drug products over the next 3 years.

Positioned For Growth

  • Increasing incidence of eye diseases among all ages.
  • Ophthalmic drugs patent cliff of $3B in next five years providing a significant growth opportunity for generic versions.
  • Canadian ophthalmic segment has a 32.6% annual growth rate.
  • Acquiring additional 70-100 ophthalmic drug products over the next 3 years.

Competitive Advantage

  • Global market opportunity for generic ophthalmics exports
  • Only four drug companies controlling the Canadian ophthalmics market
  • Canadian ophthalmic drugs among the highest priced in the world
  • Ophthalmic drugs have accelerated registration approvals as they do not require BA/BE studies to be done

Market Overview

 

 

 

 

 

TSX-V: GENX

Corporate Deck

Financials

Recent Media

Share Structure

59,359,131

Issued & Outstanding

65,112,776

Fully diluted common shares

5,753,645

Warrants & Options

For detailed financials, please visit SEDAR

Corporate Governance And Compensation Committee Charter

Stay In Touch

Trade Alert – Delivering the latest product trends and industry news straight to your inbox.


Menu